Novo Nordisk A/S – Share repurchase programme
Novo Nordisk (NVO) reported additional B-share purchases under its existing repurchase programme, bringing programme spending to DKK 6,447,270,879 through 2 October 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novo Nordisk (NVO) reported additional B-share purchases under its existing repurchase programme, bringing programme spending to DKK 6,447,270,879 through 2 October 2026. The programme has accumulated 21,845,000 B shares since its 6 May 2026 launch and allows purchases of up to DKK 11,200,000,010.45 through 1 February 2027.
Across the overall repurchase programme beginning 4 February 2026, purchases reached 36,604,179 B shares for DKK 10,247,270,869, at an average price of DKK 279.95 per share. The company expects to repurchase up to DKK 15 billion over that programme's 12-month period. Treasury holdings now total 50,644,876 B shares, corresponding to 1.1% of share capital.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 28 September, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 20,620,000 | 6,139,842,042 | |
| 28 September 2026 | 245,000 | 253.30 | 62,059,136 |
| 29 September 2026 | 245,000 | 252.74 | 61,921,920 |
| 30 September 2026 | 245,000 | 250.50 | 61,372,450 |
| 1 October 2026 | 245,000 | 249.50 | 61,126,718 |
| 2 October 2026 | 245,000 | 248.77 | 60,948,613 |
| Accumulated under the programme | 21,845,000 | 6,447,270,879 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 50,644,876 B shares of DKK 0.10 as treasury shares, corresponding to
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 2 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 36,604,179 B shares at an average share price of DKK 279.95 per B share equal to a transaction value of DKK 10,247,270,869.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Max Ung +45 3077 6414 mxun@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com | Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Company announcement No 60 / 2026
Attachments
